How to Value a Medical Supply Distributor in 2026

Medical supply distribution is one of the quieter corners of healthcare M&A, but it's also one of the most consistently profitable. I've advised on distributor sales ranging from $8M single-warehouse operations to $200M regional players, and the dynamics are remarkably consistent: buyers pay for contract stickiness, manufacturer relationships, and route density — not for revenue.

If you own a medical supply distributor and you're starting to think about an exit, here's how this market actually works in 2026, and what actually moves your valuation up or down.

The Multiple Range: 4-7x EBITDA

Medical supply distributors generally trade in the 4-7x EBITDA range, with the specific multiple driven almost entirely by contract quality and customer type. A distributor selling commodity exam gloves and syringes to independent physician offices on 30-day terms will land at the bottom of that range. A distributor with multi-year GPO agreements, exclusive manufacturer territories, and a book of hospital IDN customers can command 7x+ and occasionally higher when a strategic like Medline, Henry Schein, or Cardinal Health is the acquirer.

The spread between a 4x and a 7x business on $3M of EBITDA is $9M of enterprise value. That's not a rounding error — it's typically the difference between an owner who built contracts and one who relied on repeat orders without paperwork.

For context on how this compares to other industries, our industry multiples guide breaks down the full landscape. Medical distribution sits in the upper-middle of the distribution sector because of healthcare's recession resistance and the barriers to entry created by regulatory compliance.

Why GPO Contracts Drive Everything

Group Purchasing Organizations — Vizient, Premier, HealthTrust, and a handful of regional GPOs — control the vast majority of hospital and health system purchasing. If you hold a GPO contract, you have something most buyers can't build: distribution rights to thousands of member facilities without having to sell each one individually.

Buyers pay a meaningful premium for GPO contract holders. I've seen distributors with a single Vizient Tier 1 contract add 1.0-1.5 turns of EBITDA to their valuation compared to an otherwise identical business without GPO access. The logic is simple: GPO awards typically run 3-5 years, are rarely re-bid mid-term, and create a revenue floor the buyer can underwrite.

The catch is that GPO contracts are increasingly awarded on volume and national footprint. A $15M regional distributor may participate in a GPO contract as a subcontractor rather than a prime, which is less valuable but still meaningful. Document exactly which contracts you hold, whether you're prime or sub, the contract end dates, and the historical volume under each. Buyers will ask on day one of diligence.

Manufacturer Authorizations Are the Second Moat

The other piece of the valuation puzzle is your relationships with manufacturers. Exclusive or semi-exclusive distribution rights for a branded product line — think a territory agreement with a wound care manufacturer, an orthopedic implant company, or a specialty infusion product — create switching costs that buyers love.

I worked on a deal last year where a $22M distributor had three exclusive territory agreements representing about 40% of revenue. The base business would have valued at 5x EBITDA. The exclusives pushed the deal to 6.5x because the buyer (a larger regional distributor) knew they couldn't replicate those relationships through organic growth. The premium on $3.2M of EBITDA was $4.8M — paid for entirely by three manufacturer agreements the seller had quietly built over 15 years.

The risk cuts the other way too. If a single manufacturer represents more than 25% of your gross profit and the agreement is terminable on 30-90 day notice, buyers will haircut the value of that revenue stream or insist on escrow tied to the relationship surviving the transaction. Get multi-year written agreements with change-of-control language negotiated in advance.

Customer Mix and the Hospital Premium

Not all medical distribution customers are valued the same way:

• Hospital and IDN customers: The gold standard. Long purchasing cycles, contracted pricing, sticky relationships. Buyers pay 6-7x EBITDA for books weighted here.
• Surgery centers and specialty clinics: Growing segment with good margins and decent stickiness. Typically 5-6x EBITDA.
• Physician offices and independent practices: Fragmented, price-sensitive, and easier to lose to online competitors. 4-5x EBITDA on this revenue.
• Long-term care and home health: Thin margins, payment delays, and regulatory complexity. Often 3.5-4.5x EBITDA.

The mix matters more than the top-line number. A $25M distributor with 60% hospital revenue will outsell a $40M distributor selling mostly to physician offices every time.

What Kills Medical Distributor Value

Customer concentration above 20%. If your top customer is more than 20% of revenue, buyers will either haircut the multiple by a full turn or structure 20-30% of the purchase price as an earnout tied to that customer staying. I've seen $4M of value disappear on otherwise healthy businesses because one hospital IDN was 35% of the book.

No quality management system. Medical distributors are regulated under FDA 21 CFR Part 820 and state wholesale distribution licensing. If you don't have documented SOPs, lot tracking, recall procedures, and a designated quality officer, buyers assume there's regulatory risk and price it in. ISO 13485 certification is not required but it's a positive signal that can add 0.2-0.5x to the multiple.

Owner-operated sales. If you're the rainmaker and customers call you personally for every order, your business is deeply owner-dependent. A buyer cannot underwrite revenue tied to an individual who's leaving. Build a real sales team with documented accounts and territory assignments — even if it costs you margin for a year or two before the sale, it'll pay back 3-5x at closing.

Inventory problems. Dead stock, expired products, and slow-moving SKUs turn from an operational issue into a balance sheet dispute during diligence. Most LOIs define working capital targets, and surplus inventory you thought was an asset gets written off. Run a physical count and write down dead stock at least 12 months before going to market.

The EBITDA Adjustments That Matter

Medical distribution EBITDA is notorious for needing adjustments. Owner compensation typically needs to be normalized to a market salary of $200-275K for a general manager — anything above that flows back to EBITDA. Personal vehicles, owner health insurance, and family member salaries without corresponding work are all legitimate addbacks if you can document them.

Be careful with addbacks buyers will reject: sales rep commissions (those are real expenses), warehouse rent even if you own the building (it gets replaced with fair market rent), and one-time inventory write-downs that have happened three years in a row. If you're unsure how to think about this, our guide on SDE vs EBITDA walks through which adjustments are defensible.

Who's Buying Medical Distributors in 2026

The buyer universe has three tiers. At the top, Cardinal Health, McKesson, Medline, and Henry Schein make strategic tuck-in acquisitions of distributors with specialty capabilities or geographic gaps. These deals price at the top of the range (6.5-7.5x) but have long timelines and intense diligence.

The middle tier is private equity-backed platforms — firms like Audax, Linden Capital, and Court Square have all built medical distribution platforms through roll-ups. They typically pay 5.5-7x for quality assets and close faster than strategics.

At the bottom, independent regional distributors buy smaller competitors at 4-5x EBITDA as a way to add route density and contract coverage. These are the fastest deals but lowest multiples.

The Bottom Line

Medical supply distribution valuations aren't driven by revenue or even margin — they're driven by the quality of the paper underneath your business. Contracts, authorizations, and regulatory documentation are what buyers actually pay for. If you can spend 18-24 months before a sale tightening those things up, the payoff is usually 1.5-2x what it would be otherwise. The owners who leave the most money on the table are the ones who built great businesses on handshakes and assumed buyers would see the same thing they do.